ALTEOGEN Inc (196170) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ALTEOGEN Inc (196170) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.88 Billion ≈ $-3.31 Million USD) by net assets (₩377.92 Billion ≈ $256.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ALTEOGEN Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how ALTEOGEN Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ALTEOGEN Inc for a breakdown of total debt and financial obligations.
ALTEOGEN Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALTEOGEN Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Juniper Networks Inc
NYSE:JNPR
|
0.066x |
|
mBank SA
WAR:MBK
|
0.724x |
|
Investment AB Latour (publ)
ST:LATO-B
|
0.021x |
|
Argen-X
LSE:0QW0
|
0.008x |
|
Shengyi Electronics Co. Ltd. A
SHG:688183
|
N/A |
|
Ovintiv Inc
NYSE:OVV
|
0.080x |
|
Focus Media Information Technology Co Ltd
SHE:002027
|
0.115x |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
-0.048x |
Annual Cash Flow Conversion Efficiency for ALTEOGEN Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of ALTEOGEN Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see ALTEOGEN Inc (196170) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩274.09 Billion ≈ $185.75 Million |
₩53.04 Billion ≈ $35.95 Million |
0.194x | +468.44% |
| 2023-12-31 | ₩147.84 Billion ≈ $100.19 Million |
₩-7.77 Billion ≈ $-5.26 Million |
-0.053x | +56.29% |
| 2022-12-31 | ₩148.76 Billion ≈ $100.81 Million |
₩-17.87 Billion ≈ $-12.11 Million |
-0.120x | -73.66% |
| 2021-12-31 | ₩136.73 Billion ≈ $92.66 Million |
₩-9.46 Billion ≈ $-6.41 Million |
-0.069x | -700.12% |
| 2020-12-31 | ₩131.16 Billion ≈ $88.89 Million |
₩1.51 Billion ≈ $1.02 Million |
0.012x | -91.17% |
| 2019-12-31 | ₩69.98 Billion ≈ $47.43 Million |
₩9.13 Billion ≈ $6.19 Million |
0.131x | +195.42% |
| 2018-12-31 | ₩66.63 Billion ≈ $45.15 Million |
₩-9.11 Billion ≈ $-6.18 Million |
-0.137x | -25.37% |
| 2017-12-31 | ₩39.85 Billion ≈ $27.00 Million |
₩-4.35 Billion ≈ $-2.95 Million |
-0.109x | -56.21% |
| 2016-12-31 | ₩45.23 Billion ≈ $30.65 Million |
₩-3.16 Billion ≈ $-2.14 Million |
-0.070x | -218.91% |
| 2015-12-31 | ₩38.55 Billion ≈ $26.13 Million |
₩2.26 Billion ≈ $1.53 Million |
0.059x | +73.87% |
| 2014-12-31 | ₩35.82 Billion ≈ $24.28 Million |
₩1.21 Billion ≈ $820.03K |
0.034x | -- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more